# EDGAR Filing Document

**Accession Number:** 0000200406
**File Stem:** 0000200406-26-000089
**Filing Date:** 2026-4
**Character Count:** 8197
**Document Hash:** 0baeb28d36441f1030c68a3abe4ca093
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000200406-26-000089.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0000200406-26-000089

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260423

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260427

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JOHNSON & JOHNSON
- **CENTRAL INDEX KEY:** 0000200406
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 221024240
- **STATE OF INCORPORATION:** NJ
- **FISCAL YEAR END:** 0103

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-03215
- **FILM NUMBER:** 26902320

**BUSINESS ADDRESS:**
- **STREET 1:** ONE JOHNSON & JOHNSON PLZ
- **CITY:** NEW BRUNSWICK
- **STATE:** NJ
- **ZIP:** 08933
- **BUSINESS PHONE:** 732-524-2455

**MAIL ADDRESS:**
- **STREET 1:** ONE JOHNSON & JOHNSON PLZ
- **CITY:** NEW BRUNSWICK
- **STATE:** NJ
- **ZIP:** 08933

?xml version='1.0' encoding='ASCII'? jnj-20260423

    

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The**

**Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported):** 

**April 23, 2026**

**Johnson & Johnson** 

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **New Jersey** | **1-3215** | **22-1024240** |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

**One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933** 

**(Address of Principal Executive Offices)**

 **(Zip Code)** 

**Registrant's telephone number, including area code:**

**732-524-0400** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT**

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Stock, Par Value $1.00 | JNJ | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.700% Notes Due February 2029 | JNJ29B | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.200% Notes Due June 2032 | JNJ32 | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.050% Notes Due February 2033 | JNJ33B | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.350% Notes Due June 2036 | JNJ36A | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.350% Notes Due February 2037 | JNJ37B | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.550% Notes Due June 2044 | JNJ44 | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.600% Notes Due February 2045 | JNJ45 | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.700% Notes Due February 2055 | JNJ55 | New York Stock Exchange |

---

------

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

(a)&nbsp;&nbsp;&nbsp;&nbsp;The 2026 Annual Meeting of Shareholders of the Company was held on April 23, 2026.

(b)&nbsp;&nbsp;&nbsp;&nbsp;At the 2026 Annual Meeting of Shareholders, the shareholders:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• elected all 12 Director nominees named in the 2026 Proxy Statement to the Company's Board of Directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• approved, on an advisory basis, the executive compensation philosophy, policies and procedures described in the "Compensation Discussion and Analysis" section of the 2026 Proxy Statement and the compensation of the Company's executive officers named in the 2026 Proxy Statement, as disclosed therein;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year 2026; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• did not approve the shareholder proposal to adopt a policy requiring an independent board chair.

The following are the final voting results for each of the four items voted on at the meeting.

**1.**&nbsp;&nbsp;&nbsp;&nbsp;**Election of Directors:**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Shares For** | **Shares Against** | **Shares Abstain** | **Non-Votes** |
| M. C. Beckerle | 1717960024 | 21523602 | 3071503 | 314406723 |
| J. A. Doudna | 1722365064 | 17232471 | 2957594 | 314406723 |
| J. Duato | 1654870358 | 84725734 | 2959037 | 314406723 |
| M. A. Hewson | 1694721822 | 43362781 | 4470526 | 314406723 |
| P. A. Johnson | 1724394799 | 15093883 | 3066447 | 314406723 |
| H. Joly | 1664230485 | 75001172 | 3323472 | 314406723 |
| M. B. McClellan | 1716126914 | 23153464 | 3274751 | 314406723 |
| J. G. Morikis | 1722975295 | 16204254 | 3375580 | 314406723 |
| D. E. Pinto | 1729298557 | 10014607 | 3241965 | 314406723 |
| M. A. Weinberger | 1676844107 | 61834491 | 3876531 | 314406723 |
| N. Y. West | 1716608777 | 22801606 | 3144746 | 314406723 |
| E. A. Woods | 1682880891 | 56411905 | 3262333 | 314406723 |

---

**2.&nbsp;&nbsp;&nbsp;&nbsp;Advisory vote to approve named executive officer compensation (Say on Pay):**

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstained** | **Non-Votes** |
| 1,641,173,032 | 91,774,923 | 9,607,174 | 314,406,723 |

---

------

**3.&nbsp;&nbsp;&nbsp;&nbsp;Ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for 2026:**

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstained** | **Non-Votes** |
| 1,914,846,474 | 138,633,899 | 3,481,479 | 0 |

---

**4.&nbsp;&nbsp;&nbsp;&nbsp;Shareholder Proposal - independent board chair:**

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstained** | **Non-Votes** |
| 406,353,048 | 1,326,857,173 | 9,344,908 | 314,406,723 |

---

**Item 9.01 Financial statements and exhibits**

(d)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. |

---

------

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 27, 2026

---

| | |
|:---|:---|
| | **JOHNSON & JOHNSON** |
| | (Registrant) |
| By: | /s/ **Marc Larkins** |
|  | **Marc Larkins**<br>Corporate Secretary |

---